NCT01749540View on ClinicalTrials.gov

Study to Evaluate the Safety and Efficacy of Luspatercept (ACE-536) in Participants With Beta-thalassemia (A536-04/MK-6143-002)

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

November 11, 2015

Study Completion Date

November 11, 2015

Conditions

B-Thalassemia

Interventions

DRUG

luspatercept

subcutaneous injection

Trial Locations (8)

Unknown

Laiko General Hospital, Ampelokipi, Athens

"Ospedale A. Perriino U.O Ematologia", Brindisi

ARNAS Garibaldi - P.O. Garibaldi Centro, Catania

A.O.U. Arcispedale S. Anna, Ferrara

CEMEF Medicina 2, Modena

A.O.U. Seconda Università degli Studi di Napoli, Napoli

AORN A. Cardarelli, Napoli

A.O.U. San Luigi Gonzaga, Orbassano

All Listed Sponsors

lead

Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA

INDUSTRY

NCT01749540 - Study to Evaluate the Safety and Efficacy of Luspatercept (ACE-536) in Participants With Beta-thalassemia (A536-04/MK-6143-002) | Biotech Hunter | Biotech Hunter